Pharmaceutical
Biotechnology
Biopharmaceutical
Alexion Pharmaceuticals
$130.219876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$130.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$4.00 (-2.98%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ALXN and other stocks, options, ETFs, and crypto commission-free!
About
Alexion Pharmaceuticals, Inc. Common Stock, also called Alexion Pharmaceuticals, is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Read More Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.
Employees
2,656
Headquarters
Boston, Massachusetts
Founded
1992
Market Cap
30.00B
Price-Earnings Ratio
393.83
Dividend Yield
0.00
Average Volume
1.62M
High Today
$134.77
Low Today
$130.12
Open Price
$133.86
Volume
537.08K
52 Week High
$140.77
52 Week Low
$92.56
Collections
Pharmaceutical
Biotechnology
Biopharmaceutical
Health
Therapy
Technology
US
North America
News
Seeking AlphaMar 20
Achillion Pharmaceuticals: The Promise Of Alternative Pathway Inhibition
One of ACH-4471 weaknesses is its dosing schedule and potency and as a response, Achillion is developing more potent next-gen factor D inhibitors.
Price Paid on Robinhood
8% Higher
Right Now
52 Week Low
$92.56
Average Price Paid
$120.85
52 Week High
$140.77
Earnings
$1.25
$1.55
$1.84
$2.14
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 25, Pre-Market